| abstract |
The present invention relates to isolated antibodies, particularly monoclonal antibodies, particularly CDR-grafted humanized antibodies, that bind to RAGE proteins. Specifically, these antibodies have the ability to inhibit RAGE binding to its various ligands. The antibody or portion thereof described herein may be used to treat a disease or disorder characterized by or induced by a pathophysiological ligand of RAGE, e. G., A misfolded protein (e. G., Amyloid beta and a final glycation product) . |